Clinical trials: Movement Abnormalities
- Condition Movement Abnormalities
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Parkinson's Disease, Levodopa Induced Dyskinesia (LID)
Efficacy and Safety of Amantadine Hydrogen Chloride (HCl) ER Tablets in Parkinson's Disease Subjects With LID
The purpose of this multi-center, randomized, double-blind, parallel-group, 26 week study is to compare the efficacy and safety of two different dose levels of Amantadine Extended Release Tablets to placebo for the treatment of…
- Trial name
- ALLAY-LID-II (NCT02153632)
- Testing
- amantadine HCl ER
- Where
- 56 sites in United States, Canada and 3 more
- Volunteers
- 135 people
- Sponsor
- Adamas Pharmaceuticals, Inc.
Wilson Disease
Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease
This study is being conducted to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics of ALXN1840 versus standard of care in pediatric participants with Wilson disease (WD).
- Trial name
- NCT05047523
- Testing
- ALXN1840, Standard of Care
- Where
- 20 sites in Australia, France and 5 more
- Volunteers
- 40 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Parkinson Disease
Kinetic Tremor in Parkinsons Disease: Its Course Under Pramipexole (Mirapexin®) Treatment and Impact on Quality of Life
The study will compare the effect of pramipexole on different types of tremor and particularly kinetic tremor in early and advanced Parkinson's disease patients and will evaluate the course of tremor measured with spiralometry…
- Trial name
- NCT01100073
- Where
- 215 sites in Estonia, Latvia and 6 more
- Volunteers
- 1,703 people
- Sponsor
- Boehringer Ingelheim
Sleep Disorders
Efficacy and Safety of Circadin® in the Treatment of Sleep Disturbances in Children With Neurodevelopment Disabilities
The purpose of this study is to establish the efficacy and safety of Circadin in children with neurodevelopmental disorders and to determine the dose, this randomized, placebo-controlled study is planned to evaluate the efficacy…
- Trial name
- NCT01906866
- Testing
- Circadin 2/5/10 mg
- Where
- 28 sites in United States, Finland and 3 more
- Volunteers
- 125 people
- Sponsor
- Neurim Pharmaceuticals Ltd.
Parkinson's Disease
Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety Study
The study had three distinct parts and is described as follows: Part 1: To evaluate the dose conversion from CD-LD ER taken alone or in combination with CD-LD IR to IPX066 in subjects with advanced PD To evaluate the utility of…
- Trial name
- NCT01411137
- Testing
- IPX066
- Where
- 8 sites in United States
- Volunteers
- 43 people
- Sponsor
- Impax Laboratories, LLC
Parkinson's Disease (PD)
COmedication Study Assessing Mono- and cOmbination Therapy With Levodopa-carbidopa inteStinal Gel
The purpose of this study is to evaluate treatment of advanced Parkinson's Disease (PD) patients on levodopa-carbidopa intestinal gel (LCIG) monotherapy in a routine clinical setting.
- Trial name
- COSMOS (NCT03362879)
- Where
- 30 sites in Austria, Canada and 9 more
- Volunteers
- 412 people
- Sponsor
- AbbVie
Parkinson Disease
Fixed-Dose Trial in Early Parkinson's Disease (PD)
The purpose of this study is to evaluate the clinical efficacy, safety and pharmacokinetics (PK) of 2 fixed doses of tavapadon and placebo in participants with early PD.
- Trial name
- TEMPO-1 (NCT04201093)
- Testing
- Tavapadon
- Where
- 77 sites in United States, Australia and 10 more
- Volunteers
- 529 people
- Sponsor
- AbbVie
IDIOPATHIC PARKINSON'S DISEASE
Rotigotine Versus Placebo As Double Blind Study To Evaluate The Efficacy In Early Stage Idiopathic Parkinson's Disease Patients
The primary objective is to demonstrate that the Rotigotine transdermal patch is efficacious in Chinese subjects with early-stage idiopathic Parkinson's disease.
- Trial name
- NCT01646268
- Testing
- Rotigotine
- Where
- 24 sites in China
- Volunteers
- 249 people
- Sponsor
- UCB Pharma
Parkinson's Disease
Safety and Tolerability Trial of Switching From Ropinirole to Rotigotine
This is a Phase 3b, open-label, multicenter trial to assess the safety and tolerability of switching from ropinirole therapy to the rotigotine transdermal system and its effect on symptoms in subjects with idiopathic Parkinson's…
- Trial name
- NCT00593606
- Testing
- Rotigotine
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- UCB Pharma
Mild Cognitive Impairment, Lewy Body Dementia, Parkinson's Disease Rapid Eye Movement Sleep Behavior Disorder, Parkinson's Disease Dementia
A Study of Clenbuterol (CST-103) Co-administered With Nadolol (CST-107) in Subjects With Neurodegenerative Disorders
This is a Phase II, randomized, placebo-controlled, double-blind, crossover study on the CNS and pharmacodynamic effects of clenbuterol (CST-103) co-administered with nadolol (CST-107) in 4 subject populations with…
- Trial name
- CLIN-011 (NCT04739423)
- Where
- 7 sites in Australia, New Zealand and 1 more
- Volunteers
- 41 people
- Sponsor
- CuraSen Therapeutics, Inc.
Parkinson's Disease, Idiopathic
A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD
The purpose of this study is to measure safety and efficacy of buntanetap/posiphen capsules compared with placebo capsules in participants with early PD. Study details include: The study duration will be up to 7-8 months.
- Trial name
- NCT05357989
- Testing
- buntanetap/posiphen
- Where
- 69 sites in United States, Germany and 4 more
- Volunteers
- 523 people
- Sponsor
- Annovis Bio Inc.
Parkinson Disease
Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).
The general aim of this study is to obtain long-term safety and tolerability data on pramipexole ER, in daily doses from 0.375mg to 4.5mg once daily (q.d), in patients who have previously completed a pramipexole double-blind…
- Trial name
- NCT00601523
- Testing
- Pramipexole
- Where
- 119 sites in United States, Austria and 13 more
- Volunteers
- 511 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Parkinson's Disease
An Open-Label Extension Trial to Assess the Safety and Tolerability of Long Term Treatment of Rotigotine in Subjects With Idiopathic Parkinson's Disease
The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of rotigotine in subjects with idiopathic PD.
- Trial name
- NCT00505687
- Testing
- Rotigotine
- Where
- 26 sites in United States, Austria and 6 more
- Volunteers
- 186 people
- Sponsor
- UCB Pharma
Parkinson Disease
Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TEMPO-3)
The purpose of this study is to assess the effect of tavapadon on the change from baseline in total daily hours of "on" time without troublesome dyskinesia in L-Dopa-treated participants with Parkinson's Disease (PD) who are…
- Trial name
- NCT04542499
- Testing
- Tavapadon
- Where
- 146 sites in United States, Australia and 12 more
- Volunteers
- 507 people
- Sponsor
- AbbVie
Multiple System Atrophy
Safinamide for Multiple System Atrophy (MSA)
The study is a placebo controlled study, with two parallel arms, in which participants will be randomly assigned in a 2:1 ratio to receive either active (200 mg safinamide) or placebo in a double blind manner.
- Trial name
- NCT03753763
- Testing
- Safinamide Methanesulfonate
- Where
- 19 sites in Italy, Spain
- Volunteers
- 49 people
- Sponsor
- Zambon SpA
Parkinson Disease
A Single Oral Ascending Dose Study of BIA 9-1067 in Healthy Male Subjects
The purpose of this study was to investigate the safety, tolerability, pharmacokinetics and catechol-O-methyltransferase (COMT) activity of BIA 9-1067 in healthy male subjects after single oral ascending doses.
- Trial name
- NCT01520727
- Testing
- BIA 9-1067
- Where
- France
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Symptomatic Neurogenic Orthostatic Hypotension
Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension
To evaluate the time to treatment intervention in patients with Parkinson's Disease (PD), Multiple System Atrophy (MSA), Pure Autonomic Failure (PAF), Non-Diabetic Autonomic Neuropathy (NDAN) or Dopamine Beta Hydroxylase (DBH)…
- Trial name
- RESTORE (NCT02586623)
- Testing
- Droxidopa capsules
- Where
- 168 sites in United States
- Volunteers
- 453 people
- Sponsor
- H. Lundbeck A/S
Parkinson's Disease, Off Episodes of Parkinson Disease
A Cardiac Safety Study of an Investigational Drug to See How if Affects the Heart in People With Parkinson's Disease Complicated by Motor Fluctuations "OFF" Episodes
A cardiac safety study of an investigational drug to see how it affects the heart in people with Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes)
- Trial name
- NCT03187301
- Testing
- APL-130277, Moxifloxacin
- Where
- 15 sites in United States, Italy
- Volunteers
- 48 people
- Sponsor
- Sumitomo Pharma America, Inc.
Huntington Disease
An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Participants Who Participated in Prior Roche and Genentech Sponsored Studies
This study will evaluate the long-term safety and tolerability of RO7234292 (RG6042) in participants who have completed other F.
- Trial name
- NCT03842969
- Testing
- RO7234292 (RG6042)
- Where
- 38 sites in United States, Austria and 6 more
- Volunteers
- 236 people
- Sponsor
- Hoffmann-La Roche
Tourette Syndrome
A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS)
Standard placebo-controlled, double-blind study design (TEV-50717 [low dose and high dose] vs. placebo in a 1:1:1 ratio) was chosen to determine whether study drug treatment results in a statistically significant effect on the…
- Trial name
- ARTISTS2 (NCT03571256)
- Testing
- TEV-50717
- Where
- 56 sites in United States, Argentina and 8 more
- Volunteers
- 158 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.